Nothing Special   »   [go: up one dir, main page]

AU682278B2 - Oligomer carrier molecules in which marker groups and haptens are selectively incorporated - Google Patents

Oligomer carrier molecules in which marker groups and haptens are selectively incorporated

Info

Publication number
AU682278B2
AU682278B2 AU31649/95A AU3164995A AU682278B2 AU 682278 B2 AU682278 B2 AU 682278B2 AU 31649/95 A AU31649/95 A AU 31649/95A AU 3164995 A AU3164995 A AU 3164995A AU 682278 B2 AU682278 B2 AU 682278B2
Authority
AU
Australia
Prior art keywords
haptens
carrier molecules
marker groups
selectively incorporated
oligomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU31649/95A
Other versions
AU682278C (en
AU3164995A (en
Inventor
Andreas Finke
Rupert Herrmann
Eva Hoss
Hans-Peter Josel
Andreas Marschall
Christoph Seidel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Boehringer Mannheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4430998A external-priority patent/DE4430998A1/en
Application filed by Boehringer Mannheim GmbH filed Critical Boehringer Mannheim GmbH
Publication of AU3164995A publication Critical patent/AU3164995A/en
Application granted granted Critical
Publication of AU682278B2 publication Critical patent/AU682278B2/en
Publication of AU682278C publication Critical patent/AU682278C/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention concerns novel conjugates, process for manufacturing them, and the use of such conjugates as antigens in immunological detection processes or in DNA diagnostic procedures.
AU31649/95A 1994-07-25 1995-07-24 Oligomer carrier molecules in which marker groups and haptens are selectively incorporated Ceased AU682278C (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
DE4426276 1994-07-25
DE4426276 1994-07-25
DE4430998A DE4430998A1 (en) 1994-07-25 1994-08-31 Metal chelated peptides
DE4430973A DE4430973A1 (en) 1994-07-25 1994-08-31 Hapten-labeled peptides
DE4430973 1994-08-31
DE4430998 1994-08-31
DE4439345A DE4439345A1 (en) 1994-07-25 1994-11-04 New conjugates comprising oligomeric carrier and attached hapten(s)
DE4439345 1994-11-04
PCT/EP1995/002915 WO1996003650A1 (en) 1994-07-25 1995-07-24 Oligomer carrier molecules in which marker groups and haptens are selectively incorporated

Publications (3)

Publication Number Publication Date
AU3164995A AU3164995A (en) 1996-02-22
AU682278B2 true AU682278B2 (en) 1997-09-25
AU682278C AU682278C (en) 1998-08-27

Family

ID=

Also Published As

Publication number Publication date
WO1996003650A1 (en) 1996-02-08
FI970299A0 (en) 1997-01-24
FI970299A (en) 1997-01-24
JPH10506708A (en) 1998-06-30
CN1153555A (en) 1997-07-02
DK0774119T3 (en) 2004-07-12
PT774119E (en) 2004-07-30
CA2195752C (en) 2010-10-26
NO970130D0 (en) 1997-01-10
NO970130L (en) 1997-01-10
ATE261122T1 (en) 2004-03-15
NZ290810A (en) 1998-01-26
JP3923076B2 (en) 2007-05-30
EP0774119B1 (en) 2004-03-03
CN1178062C (en) 2004-12-01
AU3164995A (en) 1996-02-22
EP0774119A1 (en) 1997-05-21
ES2217282T3 (en) 2004-11-01
CA2195752A1 (en) 1996-02-08

Similar Documents

Publication Publication Date Title
NZ316787A (en) Methods and compositions for the selective modification of nucleic acids
AU1367095A (en) Effector proteins of rapamycin
AU4073297A (en) Methods and compositions for the detection of cervical cancer
WO1995018826A3 (en) Purified primate ctla-8 antigens and related reagents
AU1331100A (en) Cancer immunotheraphy and diagnosis using universal tumor associated antigens, including htert
PL343245A1 (en) Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses
AU4667596A (en) Mycobacterial proteins, microorganisms producing same and uses of said proteins in vaccines and for detecting tuberculosis
WO2000069896A3 (en) Molecular interactions in haematopoietic cells
EP1111385A3 (en) Enzyme-protein complex
WO2000035950A3 (en) Reagents and methods useful for detecting diseases of the breast
WO1997029199A3 (en) Prostate specific antigen peptides and uses thereof
ZA975588B (en) Isolated nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof.
PL327066A1 (en) Method of diagnosing and treating squamous cell carcinomas
DE69634077D1 (en) HAEMOPHILUS ADHESION PROTEINS
WO1999002704A3 (en) Dual specifically phosphatase and methods of use
AU8896091A (en) Labelled, modified oligonucleotides
AU682278B2 (en) Oligomer carrier molecules in which marker groups and haptens are selectively incorporated
AU5246190A (en) Retinoblastoma gene product antibodies and uses therefor
EP0220714A3 (en) Dna fragment containing the cyclodextrin-glycosyl-transferase gene, expression vector, microorganisms for expression and preparation process
WO1996040763A3 (en) Peptides for hiv-1 detection
EP0974658A4 (en) Probes for the diagnosis of infections caused by streptococcus pyogenes
AU5569600A (en) Novel protein and dna thereof
FR2657882B1 (en) DNA FRAGMENTS COMPRISING THE GENE OF 1-DEHYDROGENASE, MICROORGANISMS TRANSFORMED BY SAID FRAGMENTS AND APPLICATIONS OF SUCH FRAGMENTS AND MICROORGANISMS.
AU1144699A (en) Group of nucleic acid molecules for (salmonella) detection, nucleic acids, kit and use
CA2156397A1 (en) Rapamycin assay